Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | FDPS | P14324 | 6/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989187 | 0.89 | CYP3A4 (0.33) | CYP3A4L3MBTL1ALDH1A1FDPSCA2 | |
| SCHEMBL4188104 | 0.81 | ALDH1A1 (0.39) | CYP3A4L3MBTL1ALDH1A1FDPSCA2 | |
| SCHEMBL4188102 | 0.81 | CYP3A4 (0.40) | CYP3A4L3MBTL1ALDH1A1FDPSCA2 | |
| SCHEMBL8855572 | 0.78 | CYP3A4 (0.55) | CYP3A4L3MBTL1ALDH1A1FDPSCA2 | |
| SCHEMBL968645 | 0.76 | CYP3A4 (0.41) | CYP3A4L3MBTL1ALDH1A1FDPSCA2 | |
| SCHEMBL674509 | 0.76 | ALDH1A1 (0.50) | CYP3A4L3MBTL1ALDH1A1FDPSCA2 | |
| SCHEMBL7866461 | 0.76 | FDPS (0.54) | CYP3A4L3MBTL1ALDH1A1FDPSCA2 | |
| SCHEMBL4200100 | 0.76 | CYP3A4 (0.36) | CYP3A4L3MBTL1ALDH1A1FDPSCA2 | |
| SCHEMBL4200103 | 0.75 | ALDH1A1 (0.35) | CYP3A4L3MBTL1ALDH1A1CA2TDP1 | |
| SCHEMBL969113 | 0.75 | FDPS (0.36) | FDPSSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029613-B1 | NOVEL PHOSPHINIC ACIDS AND THEIR SULFUR DERIVATIVES AND METHODS FOR THEIR PREPARATION | CYTEC CANADA INC (CA) | 2016-07-20 | — | — | EP | claimed |
| US-9102695-B2 | Phosphinic acids and their sulfur derivatives and methods for their preparation | CYTEC TECHNOLOGY CORP. (US) | 2015-08-11 | — | — | US | claimed |
| US-8968698-B2 | Processes for recovering metals from aqueous solutions | CYTEC TECHNOLOGY CORP. (US) | 2015-03-03 | — | — | US | claimed |
| US-20140275615-A1 | NOVEL PHOSPHINIC ACIDS AND THEIR SULFUR DERIVATIVES AND METHODS FOR THEIR PREPARATION | CYTEC TECHNOLOGY CORP. (US) | 2014-09-18 | — | — | US | claimed |
| US-8764880-B2 | Phosphinic acids and their sulfur derivatives and methods for their preparation | CYTEC CANADA INC. (CA) | 2014-07-01 | — | — | US | claimed |
| US-8328900-B2 | Processes for recovering metals from aqueous solutions | CYTEC TECHNOLOGY CORP. (US) | 2012-12-11 | — | — | US | claimed |
| US-20090165598-A1 | NOVEL PHOSPHINIC ACIDS AND THEIR SULFUR DERIVATIVES AND METHODS FOR THEIR PREPARATION | CYTEC CANADA INC. (CA) | 2009-07-02 | — | — | US | claimed |
| EP-2029613-A1 | NOVEL PHOSPHINIC ACIDS AND THEIR SULFUR DERIVATIVES AND METHODS FOR THEIR PREPARATION | Cytec Canada Inc. (CA) | 2009-03-04 | — | — | EP | claimed |
| WO-2007143832-A1 | NOVEL PHOSPHINIC ACIDS AND THEIR SULFUR DERIVATIVES AND METHODS FOR THEIR PREPARATION | CYTEC CANADA INC. (CA) | 2007-12-21 | — | — | WO | claimed |
| US-9822425-B2 | Processes for recovering metals from aqueous solutions | CYTEC TECHNOLOGY CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| EP-2029613-B1 | NOVEL PHOSPHINIC ACIDS AND THEIR SULFUR DERIVATIVES AND METHODS FOR THEIR PREPARATION | CYTEC CANADA INC (CA) | 2016-07-20 | — | — | EP | disclosed |
| US-9102695-B2 | Phosphinic acids and their sulfur derivatives and methods for their preparation | CYTEC TECHNOLOGY CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150135903-A1 | PROCESSES FOR RECOVERING METALS FROM AQUEOUS SOLUTIONS | CYTEC TECHNOLOGY CORP. (US) | 2015-05-21 | — | — | US | disclosed |
| US-8968698-B2 | Processes for recovering metals from aqueous solutions | CYTEC TECHNOLOGY CORP. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140127095-A1 | PROCESSES FOR RECOVERING METALS FROM AQUEOUS SOLUTIONS | CYTEC TECHNOLOGY CORP. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8328900-B2 | Processes for recovering metals from aqueous solutions | CYTEC TECHNOLOGY CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2451985-A2 | PROCESSES FOR RECOVERING METALS FROM AQUEOUS SOLUTIONS | Cytec Technology Corporation (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110005354-A1 | PROCESSES FOR RECOVERING METALS FROM AQUEOUS SOLUTIONS | CYTEC TECHNOLOGY CORP. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005736-A2 | PROCESSES FOR RECOVERING METALS FROM AQUEOUS SOLUTIONS | CYTEC TECHNOLOGY CORP. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20090165598-A1 | NOVEL PHOSPHINIC ACIDS AND THEIR SULFUR DERIVATIVES AND METHODS FOR THEIR PREPARATION | CYTEC CANADA INC. (CA) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275615-A1 | NOVEL PHOSPHINIC ACIDS AND THEIR SULFUR DERIVATIVES AND METHODS FOR THEIR PREPARATION | PHOSPHO1, PRDX2, PRDX1 | CYP3A4 4229/4885L3MBTL1 2994/4885ALDH1A1 2940/4885 |
| US-20090165598-A1 | NOVEL PHOSPHINIC ACIDS AND THEIR SULFUR DERIVATIVES AND METHODS FOR THEIR PREPARATION | PRDX2, PRDX1, PRDX6 | CYP3A4 4136/4885L3MBTL1 3111/4885ALDH1A1 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.